Nafamostat
As of the edition of 20 October 2026, Nafamostat is a small molecule: in active development; acts on C1R, PRSS1 and TPSAB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 18, 1 stopped early
- Disease areas
- Infections; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 0 | 3 | 0 |
| Phase 1 | 3 | 2 | 1 | 0 |
| Phase 2 | 5 | 3 | 1 | 0 |
| Phase 3 | 3 | 0 | 0 | 1 |
| Phase 4 | 4 | 1 | 3 | 0 |
| All trials | 18 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Ensysce Biosciences | Lead sponsor of trials | 2020 to now |
| Chong Kun Dang Pharmaceutical | Lead sponsor of trials | 2020 to now |